Nanoligent provides protein‑based nanoparticle carriers that self‑assemble into highly stable conjugates for targeted drug delivery. Their platform enables biomarker‑guided circulation and site‑specific release of therapeutics, improving efficacy while reducing off‑target toxicity for pharmaceutical developers.
Funding
$14.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current systemic drug delivery often lacks specificity, leading to off‑target effects and limited efficacy, especially for cancer therapies that require precise targeting of tumor biomarkers. Existing delivery platforms can be unstable in vivo, reducing therapeutic concentration at the disease site and increasing toxicity.
Solution
Nanoligent has engineered protein‑based conjugate nanoparticles that self‑assemble into highly stable architectures for in‑body administration. These nanoparticles can be programmed to recognize specific biological markers, enabling targeted circulation and site‑specific release of therapeutic payloads. The protein scaffold provides intrinsic biocompatibility and resistance to degradation, maintaining structural integrity throughout systemic transport. By coupling the drug to the nanoparticle surface, the platform delivers higher concentrations directly to the intended tissue while minimizing exposure to healthy cells. The technology is being advanced with a first candidate aimed at delivering an affordable cancer treatment, and the modular design allows adaptation to other disease biomarkers.
Target Audience
Primary customers are pharmaceutical developers and biotech companies seeking a reliable, targeted delivery system for oncology drugs and other therapeutics that require biomarker‑directed localization.
Features
- Protein‑derived nanoparticle carrier with engineered conjugation sites for precise drug attachment
- High in‑vivo stability achieved through robust protein folding and cross‑linking chemistry
- Biomarker‑guided targeting via surface ligands that bind selectively to disease‑specific receptors
- Controlled release mechanism that activates drug release upon reaching the target microenvironment
- Scalable manufacturing process compatible with standard biopharmaceutical production pipelines